Glanbia 2025 Results: Strategic Pivot Amid Mixed Performance, Unveils New €100m Buyback

FY25 takeaways: revenue up, PN margin squeeze, cash returns stepped up

Glanbia’s 2025 numbers are a mixed bag in the right ways. Group revenue edged up to $3,946.4 million, but EBITDA slipped to $499.1 million as record whey costs hit Performance Nutrition (PN). Adjusted EPS was 134.93 $cent, down 3.4% on a constant currency basis, while basic EPS rose 19.7% thanks to lower exceptional charges.

Despite margin pressure, cash generation was excellent. Operating cash conversion hit 91.0%, the dividend was lifted 10% to 42.87 €cent, and €197 million of shares were bought back. The Board has now authorised a further €100 million of buybacks for 2026.

Key numbers you should know

Jargon buster: EBITDA is operating profit before interest, tax, depreciation and amortisation. “bps” means basis points, where 100 bps equals 1%. “Like-for-like” strips out acquisitions, disposals and calendar quirks to show underlying growth.

Segment deep dive: where the gears turned

Performance Nutrition – Optimum Nutrition momentum, whey costs bite

• Revenue: $1,801.1 million (slightly lower as disposals and the prior 53rd week offset underlying growth).
• Pro-forma LFL revenue (ex SlimFast and Body & Fit): +4.5% with volume +3.6% and price +0.9%.
• Optimum Nutrition LFL revenue: +6.4%, with double digit volume growth in H2.
• EBITDA margin: 13.0% vs 16.9% in 2024, a 390 bps reported decline due to record whey input costs.

Opinion: the ON brand is clearly still winning in key markets, especially internationally. The issue is cost, not demand. If whey prices normalise, PN margins have room to recover. The disposal of SlimFast and Body & Fit should also sharpen focus on core performance nutrition.

Health & Nutrition – scale building, margins up

• Revenue: $628.5 million, +11.5% constant currency, with LFL +6.8% driven by strong volumes (+7.4%).
• EBITDA: $115.8 million, +16.7%, margin up 80 bps to 18.4%.
• Drivers: full year contribution from Flavor Producers, solid premix and flavour solutions demand in Europe and Asia. Tariffs were a headwind in H2.
• M&A: Sweetmix acquired in Brazil (~$41m initial) and Scicore in India (~$16m including deferred) completed post year end.

Opinion: H&N has become a high quality, higher margin engine. The push into Latin America and India adds local manufacturing and customer proximity. Watch the tariff situation, but the margin range of 17% to 19% looks well supported.

Dairy Nutrition – protein strength offsets weaker cheese

• Revenue: $1,516.8 million, +2.8% constant currency. LFL +5.0% with volume +4.2% and price +0.8%.
• EBITDA: $149.5 million, up 1.7%. Margin 9.9% (slightly lower by 10 bps).
• Context: strong whey prices and protein solutions demand, partly offset by negative cheese markets in H2.

Opinion: steady execution with a helpful whey backdrop. The modest margin dip underlines the mixed dairy pricing environment, but the pivot toward value added protein solutions is the right direction of travel.

Cash, dividends and buybacks: a year of strong returns

OCF of $454.4 million and 91.0% conversion show tight cash control. Free cash flow was $359.8 million after interest, tax and leases. Capital expenditure was $84.8 million, of which $51.2 million was strategic. For 2026, capex is guided to $100 million to $110 million, focused on H&N capacity in the US, China and Europe.

Shareholder returns stepped up: total dividend increased 10% to 42.87 €cent and approximately €197 million of shares were repurchased and cancelled at an average price of €13.10. The Board has authorised a further €100 million in buybacks for 2026, with the first €50 million tranche launching today.

Net debt rose to $526.0 million and leverage to 1.08x adjusted EBITDA, still comfortably low given $1.4 billion of committed facilities and 2.7 years average maturity.

Strategy in motion: portfolio reshaped and efficiency drive

• Portfolio optimisation: disposal of non-core SlimFast and Body & Fit completed in 2025.
• Selective M&A: Sweetmix and Scicore expand H&N’s footprint in Latin America and India and add in-market manufacturing that can support both H&N and PN.
• Transformation programme: targeting at least $60 million in annual cost savings by 2027. FY25 exceptional costs totalled $55.4 million for advisory and people-related items, with total exceptional items of $122.8 million pre-tax.

Opinion: this is a clear strategic pivot to higher quality growth and simpler execution. Disposals reduce distraction, acquisitions add local scale, and the transformation programme should underpin margins over the medium term.

2026 outlook and medium term targets

• FY26 guidance: adjusted EPS growth of 7% to 11% at constant currency and operating cash conversion of 85%+.
• Segment ambitions for 2026-2028:
  • PN organic revenue growth 5% to 7% (excluding disposed brands) and up to 250 bps total EBITDA margin progression from the FY25 base.
  • H&N organic revenue growth 4% to 6% with EBITDA margin 17% to 19%.
  • DN annual EBITDA range $150 million to $160 million.

Opinion: the targets look achievable if whey costs ease and PN’s H2 momentum persists. H&N should continue to be the margin anchor. DN guidance implies stability rather than fireworks.

My take: why it matters for shareholders

Positives

• Underlying demand is healthy across all three segments, with LFL growth and strong volumes.
• Cash generation is a real strength, funding a higher dividend and material buybacks.
• Strategic clean-up reduces complexity and should improve PN quality over time.
• Balance sheet flexibility remains intact with leverage at 1.08x.

Watch-outs

• PN margins were squeezed to 13.0% by record whey prices. Cost relief is the swing factor for FY26.
• Tariffs weighed on H&N in H2, and management flags broader geopolitical and trade risks.
• Return on capital employed eased to 11.3% from 12.4% as PN profitability softened.
• Exceptional cash costs are ongoing as the transformation programme progresses.

What to track in 2026

• Whey and cheese pricing trends and PN gross margin recovery.
• Optimum Nutrition consumption growth in the US and International as a proxy for brand momentum.
• Delivery of transformation savings and OCF conversion staying above 85%.
• Ramp-up of H&N capacity in the US, China and Europe, plus integration of Sweetmix and Scicore.
• DN EBITDA performance within the $150 million to $160 million corridor.

Bottom line

Glanbia’s FY25 shows resilient top-line growth and enviable cash discipline, masked somewhat by a cyclical cost headwind in PN. With the portfolio streamlined, targeted acquisitions in place, and a beefed-up buyback, management is backing its outlook of 7% to 11% adjusted EPS growth in 2026. If whey costs cooperate, PN margins should rebuild, which would let the cash story translate more cleanly into earnings growth and shareholder returns.